Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Abstract

Background Obesity has been linked to increased mortality in several cancer types; however, the relationship between obesity and survival in metastatic melanoma is unknown. The aim of this study was to examine the association between BMI, progression-free survival (PFS), and overall survival (OS) in metastatic melanoma. Methods This study included 6 independent cohorts for a total of 1918 metastatic melanoma patients. These included two targeted therapy cohorts [randomized control trials (RCTs) of dabrafenib and trametinib (n=599) and vemurafenib and cobimetinib (n=240)], two immunotherapy cohorts [RCT of ipilimumab + dacarbazine (DTIC) (n=207) and a retrospective cohort treated with anti-PD-1/PDL-1 (n=331)], and two chemotherapy cohorts [RCT DTIC cohorts (n=320 and n=221)]. BMI was classified as normal (BMI 18 to <25; n=694 of 1918, 36.1%) overweight (BMI 25-29.9; n=711, 37.1%) or obese (BMI≥30; n=513, 26.7%). The primary outcomes were the association between BMI, PFS, and OS, stratified by treatment type and sex. These exploratory analyses were based on previously reported intention-to-treat data from the RCTs. The effect of BMI on PFS and OS was assessed by multivariable-adjusted Cox models in independent cohorts. In order to provide a more precise estimate of the association between BMI and outcomes, as well as the interaction between BMI, sex, and therapy type, adjusted hazard ratios were combined in mixed-effects meta-analyses and heterogeneity was explored with meta-regression analyses. Findings In the pooled analysis, obesity, as compared to normal BMI, was associated with improved survival in patients with metastatic melanoma [average adjusted hazard ratio (HR) and 95% CI: 0.77 (0.66-0.90) and 0.74 (0.58-0.95) for PFS and OS, respectively]. The survival benefit associated with obesity was restricted to patients treated with targeted therapy [0.72 (0.57-0.91) and 0.60 (0.45-0.79) for PFS and OS, respectively] and immunotherapy [0.75 (0.56-1.00) and 0.64 (0.47-0.86)]. No associations were observed with chemotherapy [0.87 (0.65-1.17) and 1.03 (0.80-1.34); treatment p for interaction = 0.61 and 0.01, for PFS and OS, respectively]. The prognostic effect of BMI with targeted and immune therapies differed by sex with pronounced inverse associations in males [PFS 0.67 (0.53-0.84) and OS 0.53 (0.40-0.70)], but not females [PFS 0.92 (0.70-1.23) and OS 0.85 (0.61-1.18), sex p for interaction= 0.08 and 0.03, for PFS and OS, respectively] Interpretation Obesity is associated with improved PFS and OS in metastatic melanoma, driven by strong associations observed in males treated with targeted or immune therapy. The magnitude of the benefit detected supports the need for investigation into the underlying mechanism of these unexpected observations Funding ASCO/CCF Young Investigator Award and ASCO/CCF Career Development Award to JLM

The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma

“…In addition, the the rising obesity epidemic in the U.S. has led to increase use of NSAIDs and other medications, which has important implications in the outcomes of patients with melanoma. A study from our groups demonstrated a significant survival benefit for obese men who were treated with immunotherapy and targeted therapy, which perhaps could be confounded by concurrent medication . However, we did not observe a clear contributor to such an association in this study.…”

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer

“…57 Even more perplexing is the recent report that increasing BMI in male melanoma patients correlates with improved response to immunotherapy, regardless of the extent of obesity. 58 The biological basis for this intriguing clinical observation is not clear, nor is it known whether the protective effect of obesity is specific to melanoma. However, it is worth noting that many obese male melanoma patients in this clinical study received anti-diabetic drugs, 58 which have been shown to enhance the antitumor activity of anti-PD-1 blockade in preclinical melanoma models.…”

The evolution of body composition in oncology—epidemiology, clinical trials, and the future of patient care: facts and numbers

“…15 There are several proposed explanations for the observation that higher BMI is associated with improved overall Figure 1 The effects of body mass index across the cancer continuum. 29 Moreover, in a pooled analysis of solid and hematologic malignancies, sex-stratified analysis demonstrated that a BMI ≥25 kg/m 2 was associated with improved overall survival in males [HR: 0.82; P = 0.003] but not in females [HR: 1.04; P = 0.86]. The interval along the cancer continuum where the higher body mass index begins to switch from a deleterious risk factor to an advantageous risk factor, and why, is not yet known.…”